|
Glycogenolytic
H04A Glycogenolytic hormones H04AA Glycogenolytic hormones :H04AA01 Glucagon :H04AA02 Dasiglucagon Dasiglucagon, sold under the brand name Zegalogue, is a medication used to treat severe hypoglycemia in people with diabetes. The most common side effects include nausea, vomiting, headache, diarrhea, and injection site pain. Dasiglucagon wa ... References H04 {{Pharmacology-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Glucagon (medication)
Glucagon, sold under the brand name Baqsimi among others, is a medication and hormone. As a medication it is used to treat hypoglycemia, low blood sugar, beta blocker overdose, calcium channel blocker overdose, and those with anaphylaxis who do not improve with epinephrine. It is given by intravenous, injection into a vein, intramuscular, muscle, or Subcutaneous injection, under the skin. A version Nasal administration, given in the nose is also available. Common side effects include vomiting. Other side effects include low blood potassium and low blood pressure. It is not recommended in people who have a pheochromocytoma or insulinoma. Use in pregnancy has not been found to be harmful to the baby. Glucagon is in the glycogenolytic family of medications. It works by causing the liver to break down glycogen into glucose. Glucagon was approved for medical use in the United States in 1960. It is on the WHO Model List of Essential Medicines, World Health Organization's List of E ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Dasiglucagon
Dasiglucagon, sold under the brand name Zegalogue, is a medication used to treat severe hypoglycemia in people with diabetes. The most common side effects include nausea, vomiting, headache, diarrhea, and injection site pain. Dasiglucagon was approved for medical use in the United States in March 2021. Medical uses Dasiglucagon is indicated for the treatment of severe hypoglycemia in people aged six years of age and older with diabetes. Contraindications Dasiglucagon is contraindicated in people with pheochromocytoma or insulinoma. Pharmacodynamics Dasiglucagon elevates blood glucose levels in normal and hypoglycemic conditions. In adult patients with type 1 diabetes, the average increase in glucose levels at 90 minutes after dasiglucagon administration was 168 mg/dL. For pediatric patients aged seven to 17 years with type 1 diabetes, the mean glucose increase at 60 minutes post-administration was 162 mg/dL. A study conducted on Danish patients with type 1 diabetes (T ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
